Skip to main content
. Author manuscript; available in PMC: 2023 Mar 21.
Published in final edited form as: Gynecol Oncol. 2021 Feb 5;161(2):595–600. doi: 10.1016/j.ygyno.2021.01.040

Table 2:

Cancer and treatment characteristics of respondents

Characteristics All
respondents
(n=334)
High
financial
toxicity
(n=162)
Low financial
toxicity
(n=172)
P value a
Cancer site
Ovarian 209 (63) 104 (64) 105 (61) <0.001
Uterine 76 (23) 25 (15) 51 (30)
Cervical 49 (15) 33 (20) 16 (10)
Stage
I 102 (31) 45 (28) 57 (33) 0.72
II 35 (10) 20 (12) 15 (9)
III 132 (40) 64 (40) 68 (40)
IV 40 (12) 21 (13) 19 (11)
Not sure 25 (7) 12 (7) 13 (8)
Years since diagnosis 5 (2-10) 5 (2-9) 5 (2-10) 0.74
Initial treatment
Surgery and chemotherapy 195 (58) 95 (59) 100 (58) 0.76
Surgery followed by radiation 16 (5) 6 (4) 10 (6)
Surgery followed by chemotherapy and radiation 22 (7) 10 (6) 12 (7)
Chemotherapy and radiation 6 (2) 4 (2) 2 (1)
Surgery only 88 (26) 43 (27) 45 (26)
Chemotherapy only 5 (2) 2 (1) 3 (2)
Other 2 (1) 2 (1) 0 (0)
Type of initial surgery
Open 211 (66) 98 (64) 113 (68) 0.32
Laparoscopic 95 (30) 46 (30) 49 (29)
Not sure 15 (5) 10 (6) 5 (3)
Complications from surgery 52 (16) 33 (21) 19 (11) 0.02
Cancer recurred 82 (25) 44 (27) 38 (22) 0.28
Current condition of disease
In remission 193 (58) 84 (52) 109 (63) 0.08
On active treatment 94 (28) 55 (34) 39 (23)
Receiving palliative care or hospice 3 (1) 2 (1) 1 (1)
Other or missing 44 (13) 21 (13) 23 (13)

Values reported as N (%) or median (interquartile range) Percentages may not add to 100 due to rounding

a

Chi-square or Fisher’s exact test for categorical variables and Wilcoxon rank sum test for continuous variables.